Sotatercept-csrk (Winrevair; Merck &Co. Inc.) is an activin signaling inhibitor indicated for the treatment of adults with World Health Organization (WHO) Group 1 pulmonary arterial hypertension to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events.
Publications
Hayes Publications are available through the Hayes Knowledge Center, a portal to world-class research and unbiased analyses on the clinical, financial, and risk impacts of emerging, controversial, and disruptive healthcare technologies.Every Hayes publication is developed by multidisciplinary teams of clinicians and scientists using rigorous methods grounded in internally recognized standards for systematic review and Health Technology Assessment. Learn more about these evidence resources and see sample titles below.
See below for some of our recent publications.
The Spanner Prostatic Stent (SRS Medical) for Primary Treatment of Male Bladder Outlet Obstruction
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of The Spanner Prostatic Stent (SRS Medical) for primary treatment of male bladder outlet obstruction for urinary function, symptom relief, and quality of life improvement.
Afamitresgene Autoleucel (Adaptimmune Therapeutics) for Advanced Synovial Sarcoma
Afamitresgene autoleucel is an investigational autologous engineered T-cell therapy for the treatment of HLA-A*02 positive patients with advanced synovial sarcoma expressing the MAGE-A4 antigen.
Minimally Invasive Posterior Sacroiliac Joint Fusion Using a Bone Allograft for Management of Sacroiliac Joint Pain
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of minimally invasive posterior sacroiliac joint (SIJ) fusion using engineered bone allografts placed within the SIJ for management of chronic SIJ pain.
Atidarsagene Autotemcel (Lenmeldy; Orchard Therapeutics) for Metachromatic Leukodystrophy
Atidarsagene autotemcel (Lenmeldy; Orchard Therapeutics) is an autologous hematopoietic stem cell-based gene therapy indicated for the treatment of children with presymptomatic late infantile, presymptomatic early juvenile, or early symptomatic early juvenile metachromatic leukodystrophy (MLD).
Vowst (Fecal Microbiota Spores, Live-brpk; Seres Therapeutics Inc.) for Prevention of Recurrent Clostridioides Difficile Infection
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of Vowst (fecal microbiota spores, live-brpk; formerly SER-109) for prevention of recurrent Clostridioides difficile infection (rCDI).
Blarcamesine (Anavex 2-73; Anavex Life Sciences Corp.) for Alzheimer Disease
Blarcamesine (Anavex 2-73; Anavex Life Sciences Corp.) is an investigational oral small molecule sigma-1 receptor agonist for treatment of early Alzheimer disease.
AGENT Drug-Coated Balloon (Boston Scientific Corp.) for Coronary In-stent Restenosis
The AGENT Drug-Coated Balloon (Boston Scientific Corp.) is a paclitaxel-coated balloon catheter indicated for treatment of coronary in-stent restenosis (ISR). It is intended to be used after appropriate vessel preparation in adult patients undergoing percutaneous coronary intervention (PCI) in coronary arteries 2.0 millimeters (mm) to 4.0 mm in diameter and lesions up to 26 m…
Rebyota (Fecal Microbiota, Live-jslm) for Prevention of Recurrent Clostridioides Difficile Infection
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of Rebyota (fecal microbiota, live-jslm) for prevention of recurrent Clostridioides difficile infection (rCDI).
ProSense System (IceCure Medical) for Low-Risk Early-Stage Breast Cancer
The ProSense system (IceCure Medical) is a minimally-invasive, imaging-guided, cryoablation system proposed for treatment of low-risk early-stage breast cancer in patients who are not suitable candidates for surgical alternatives.